Iomai Patch-Based Vaccine Cut Rate of Travelers' Diarrhea by 75 Percent in Phase 2 F... (y be near aturning point in the preventi...)

Iomai Patch-Based Vaccine Cut Rate of Travelers' Diarrhea by 75 Percent in Phase 2 Field Study

Date:9/18/2007

y be near a turning point in the prevention of this common, often-serious disease," said Herbert L. DuPont, M.D., professor and director of the Center for Infectious Diseases at The University of Texas School of Public Health and the principal investigator on the trial. "If Phase 3 trials for the vaccine validate these results, those of us in travel medicine will have an excellent new weapon in our arsenal."

The research was conducted in collaboration with researchers from the Johns Hopkins Bloomberg School of Public Health and the University of Texas School of Public Health.

Iomai plans to begin a Phase 3 program for the needle-free vaccine patch vaccine in 2008.

"We are moving this product ahead as quickly as possible," said Chief Executive Officer Stanley C. Erck. "This is a pressing, unmet medical need. Travelers' diarrhea is the most common travel ailment in the world, yet there are no effective vaccines available for the condition. A recently completed market study suggests that there is a $750 million market for effective protection against travelers' diarrhea, an opportunity that we are well-positioned to target."

About the Phase 2 Trek Study

The Trek Study followed 170 travelers to Mexico and Guatemala. Each volunteer received either two doses of the Iomai vaccine patch or a placebo, 2 to 3 weeks apart, with the last dose administered a week before travel. Travelers kept detailed diaries and received in-country checkups. The study met its primary endpoints, which were designed to evaluate the safety of the vaccine and the incidence of enterotoxigenic E. coli (ETEC) bacteria -- the most common cause of travelers' diarrhea. No vaccine-related serious adverse events were reported.

Of the few vaccinated patients who were sickened, the diarrhea lasted only half a day on average, while those in the placebo group endured two days of illness and more than twice as many loose stools. Although not statistically significant, the fre
'/>"/>

SOURCE Iomai Corporation
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Vaccine to quit smoking?
2. First Vaccine Designed for Africa Cleared for Testing in Humans
3. New hope for cancer victims – will vaccine cure the deadly bug
4. Vaccine for Alzheimer’s diseas
5. New vaccine helps allergy and asthma patients
6. Man against HIV – new vaccine ready for human trials
7. New vaccine helps allergy and asthma patients
8. Development of AIDS vaccine -- Chiron Corp in talks with four Indian cos
9. HIV did not arise from polio vaccine
10. Double impact vaccine
11. Vaccine Reduces antibiotic-resistant infections in Children

Post Your Comments:

(Date:12/15/2009)... of cardiovascular event, suicide goes up within a ... Dec. 15 (HealthDay News) -- Emotional stress can ... risk for cardiovascular events and suicide, a new ... 168,584 Swedish men diagnosed with prostate cancer between ... percent) experienced a cardiovascular event within a year ...

(Date:12/15/2009)... -- Reportlinker.com announces that a new ... its catalogue: ,, In-Vitro Diagnostic ... and its International Trade [Q4 2009 ... ,, The newly published In-Vitro Diagnostic ... latest market research on the industry. ...

(Date:12/15/2009)... Dec. 15 Reportlinker.com announces ... is available in its catalogue: ,, ... Diseases Therapeutics - Market Forecasts to ... Deals Analysis ,, ... ,, The author has released its ...

(Date:12/15/2009)... Aon Consulting, the global human capital consulting ... AON ), today announced Lisa Zeitel has ... with the Health & Benefits Practice and ... ,, (Logo: http://www.newscom.com/cgi-bin/prnh/20041215/CGW049LOGO ) ,, ... under the direction of Aon Consulting,s Pharmacy ...

(Date:12/15/2009)... FOREST, Ill. and CHENNAI, India, Dec. 15 ... HSP ), the world leader in generic ... Ltd. (BSE: 524372, NSE: ORCHIDCHEM), a leading ... generic beta-lactam antibiotics manufacturers globally, today announced ... generic injectable finished-dosage form pharmaceuticals business for ...

[0] Stress From Prostate Cancer Diagnosis May Be Fatal [0] Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition][0] Reportlinker Adds The Future of Respiratory Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis [0] Aon Consulting Adds Senior Vice President to National Pharmacy Practice [0] Hospira to Acquire Orchid's Generic Injectable Pharmaceuticals Business

... had developed a device that will use light emissions ... //part of plaque formation in the condition of atherosclerosis. ... device that stimulates, collects and measures light emissions from ... of inflammatory cells that are associated with critical atherosclerotic ...

... one policeman and affected at least 20 deployed to fight ... ,The state government has deployed over a hundred men ... of Sambalpur district where Maoists had killed five people last ... where we are posted. We are not even getting clean ...

... network model of a molecular community in brain cells ... side effects of new drugs. Researchers from Mount Sinai ... in the latest issue of journal Science. , ... how connections within these communities enable groups of molecules ...

... the spice turmeric its yellow color, has come under ... its cancer-fighting abilities // . ,Researchers say ... block a key protein associated with esophageal cancer, known ... “ a shot in the arm for research,” ...

... time for meditation, yoga or even a trip to ... very compact these days. Thanks to the Chocolate-coated stress ... soon. ,The chocolate-like product comprises various nutraceutical herbs ... been developed by National Botanical Research Institute (NBRI), Lucknow., ...

... body from tissue damage has also been found to increase ... cells survive the effects of toxic chemotherapeutic agents // . ... of tumors in mice following exposure to a carcinogen. The ... two sets of mice, which are genetically dissimilar with respect ...

Other Medicine News:Health News:Researchers Develop Device For Detecting Atherosclerotic Plaques 2 Health News:The effects of Curcumin: a natural pigment in turmeric explored for its anti-cancer properties 2

Researchers Develop Device For Detecting Atherosclerotic Plaques Policemen face trouble fighting malaria Scientists Developed Map For Brain Molecular Communities The effects of Curcumin: a natural pigment in turmeric explored for its anti-cancer properties Under Stress? All You Need Is A Chocolate To Melt In Your Mouth Tumour risk increased by tissue protective protein

(Date:12/15/2009)... Flextronics (Nasdaq: FLEX ) today ... announced acquisition of SloMedical S.R.O., a leading ... from tubing sets to complex devices for ... provides a broad set of capabilities to ... Terms of the deal were not disclosed. ...

(Date:12/15/2009)... 15 Cumberland Pharmaceuticals Inc. ... new top-line results for a patient preference study ... a prescription laxative packaged as a crystalline powder, ... Kristalose is the only prescription-strength laxative available in ... patients with a recent diagnosis of chronic constipation ...

(Date:12/15/2009)... Pa., Dec. 15 Certified healthcare providers ... of complications from the H1N1 flu virus may ... it, the Department of Health announced today. ... to everyone because approximately 3.2 million doses of ... administered it to individuals in the priority groups. ...

Breaking Medicine Technology:Flextronics Completes SloMedical Acquisition 2 Kristalose(R) Preferred by Patients With Chronic Constipation Compared to Similar Products in a Recent Study 2 Kristalose(R) Preferred by Patients With Chronic Constipation Compared to Similar Products in a Recent Study 3 Department of Health Urges Expanded H1N1 Vaccination Efforts to Include All Patients 2 Ohio Man Top Bidder for Preakness Winners Halter First of Five Items in Horses Season Long Auction Series 53101 1 Ohio Man Top Bidder for Preakness Winners Halter First of Five Items in Horses Season Long Auction Series 53101 2 Medical Transcription Service MxSecure Partners with CHV to Enhance Community Health Care 53098 1 Medical Transcription Service MxSecure Partners with CHV to Enhance Community Health Care 53098 2 Medical Transcription Service MxSecure Partners with CHV to Enhance Community Health Care 53098 3 Birdies for Breast Cancer Announces Fifth Annual Charity Golf Classic Hosted by Top Womens Golfer Cristie Kerr 53095 1 Birdies for Breast Cancer Announces Fifth Annual Charity Golf Classic Hosted by Top Womens Golfer Cristie Kerr 53095 2

[0] Flextronics Completes SloMedical Acquisition [0] Kristalose(R) Preferred by Patients With Chronic Constipation Compared to Similar Products in a Recent Study [0] Department of Health Urges Expanded H1N1 Vaccination Efforts to Include All Patients

... - INNOVIVE Pharmaceuticals,Inc. (OTCBB: IVPH) today announced ... of INNO-406, an orally bioavailable dual Bcr-Abl ... leukemia, will be,presented at the 43rd American ... takes place June 1- 5, 2007 at ...

... Vical,Incorporated today announced that a measles DNA ... protective,levels of neutralizing antibodies in juvenile (1 ... complete protection following,challenge more than one year ... no clinical signs of disease and no,detectable ...

Other Medicine Technology:Innovive Pharmaceuticals to Present Interim Data from Phase I Study,of INNO-406 at the American Society of Clinical Oncology Annual,Meeting 2 Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term,Protection and Sterilizing Immunity in Nonhuman Primates 2 Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term,Protection and Sterilizing Immunity in Nonhuman Primates 3 Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term,Protection and Sterilizing Immunity in Nonhuman Primates 4

Innovive Pharmaceuticals to Present Interim Data from Phase I Study,of INNO-406 at the American Society of Clinical Oncology Annual,Meeting Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term,Protection and Sterilizing Immunity in Nonhuman Primates

The Thrombex PMT system is a self-contained, disposable clot-removal device that uses a motor-driven catheter and vacuum source to break up and remove thrombi from a hemodialysis graft....

... designed to remove thrombus in diameters ... travel backwards at half the speed ... pressure zone causing a vacuum effect. ... where it is fragmented by the ...

... The AngioJet Xpeedior+120 Rheolytic Thrombectomy catheter is ... performance. Powerful saline jets create a low ... a vacuum effect. Thrombus is drawn into ... the jets, and removed from the body.,AngioJet ...

... Mapping System combines the legendary accuracy of ... of Windows* software. It integrates seamlessly ... tools that enhance your clinical capabilities in ... the future of EP. The intended ...

Medicine Products:

Thrombex PMT System AVX Catheter Xpeedior +120 Catheter Carto XP Electroanatomical Mapping System

Iomai Patch-Based Vaccine Cut Rate of Travelers' Diarrhea by 75 Percent in Phase 2 F...(y be near aturning point in the preventi...),Health